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Background: The Cryopyrin-Associated Periodic Syndromes (CAPS) are a group of rare hereditary autoinflammatory
diseases and encompass Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and
Neonatal Onset Multisystem Inflammatory Disease (NOMID). Canakinumab is a monoclonal antibody directed
against IL-1 beta and approved for CAPS patients but requires post-approval monitoring due to low and short
exposures during the licensing process. Creative approaches to observational methodology are needed, harnessing
novel registry strategies to ensure Health Care Provider reporting and patient monitoring.
Methods: A web-based registry was set up to collect information on long-term safety and effectiveness of
canakinumab for CAPS.
Results: Starting in November 2009, this registry enrolled 241 patients in 43 centers and 13 countries by December
31, 2012. One-third of the enrolled population was aged < 18; the overall population is evenly divided by gender.
Enrolment is ongoing for children.
Conclusions: Innovative therapies in orphan diseases require post-approval structures to enable in depth
understanding of safety and natural history of disease. The rarity and distribution of such diseases and
unpredictability of treatment require innovative methods for enrolment and follow-up. Broad international practice-
based recruitment and web-based data collection are practical.
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The treatment experiences of patients with rare diseases
are difficult to track and monitor. Cryopyrin-Associated
Periodic Syndromes (CAPS), specifically Familial Cold
Autoinflammatory Syndrome (FCAS), Muckle-Wells Syn-
drome (MWS), and Neonatal Onset Multisystem Inflam-
matory Disease (NOMID), are a group of rare hereditary
autoinflammatory diseases, with estimated population fre-
quency ranging from 1–3 per million [1]. These syn-
dromes are typically a result of an autosomal dominant or
de novo mutation of the cold-induced auto-inflammatory
syndrome 1 (CIAS1)/nod-like receptor protein 3 (NLRP3)
gene on chromosome 1 [2]. Although it remains poorly* Correspondence: paola.primatesta@novartis.com
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reproduction in any medium, provided the orunderstood precisely how CIAS/NLRP-3 mutations cause
inflammatory diseases, it is known that the protein
encoded by this gene, NALP3 or cryopyrin, interacts with
other intracellular proteins to form an intracellular com-
plex called the inflammasome, resulting in an overproduc-
tion of active interleukin 1 (IL-1) beta, a proinflammatory
cytokine [2,3].
CAPS generally manifest as life-long episodes of recur-
rent fever accompanied by differing degrees of neutrophil-
mediated systemic inflammation. They are now regarded
as a spectrum of overlapping traits and differences in se-
verity, rather than distinct genetic disorders [4].
FCAS and MWS, on the less severe end of the spectrum,
are typically first noted in infancy, early childhood or ado-
lescence; while NOMID, also known as Chronic Infantile
Neurologic Cutaneous Articular (CINCA) syndrome is atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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neonatal period with multi-organ system inflammatory in-
volvement, including significant central nervous system
manifestations, not seen in other forms of CAPS.
Knowledge of the disease, although improving, is still
limited. Disease symptoms generally appear in early
childhood, but sensorineural deafness, one characteristic
feature of MWS, develops in up to two-thirds of patients
in later childhood and progresses through adulthood.
Systemic amyloidosis develops in up to 25% of MWS pa-
tients and often leads to renal failure in adulthood [5].
The severity of NOMID is variable, and death may occur
in young adulthood in 20% of the patients because of in-
fection, secondary amyloidosis, or cachexia [6]. Clinical
experience is based on few specialists and centres in any
country, each caring for a very limited number of pa-
tients. Various symptomatic treatments are used to
alleviate the pain and discomfort associated with the in-
flammatory flares, with limited success. Many patients
are prescribed corticosteroids, which, although in high
doses can reduce symptoms, cannot be used long-term
because of side effects. With the identification of the
genetic basis for the disease and the common pathway
of IL-1 beta activation, new approaches to treat these
conditions have been identified. Canakinumab, unlike
other IL-1 inhibitor agents (e.g. anakinra or rilonacept),
specifically blocks only IL-1 beta, the form of the IL-1
that mediates disease flares in these auto-inflammatory
diseases. The efficacy and safety profile of canakinumab
was demonstrated in the clinical trials carried out during
the development program. Though exact prevalence is
unknown, based on an estimate of one case per million
people, canakinumab has been used for treatment
of >65% of the target population [unpublished internal
data]. As with all very rare (orphan) diseases, the clinical
trials included a very limited number of patients treated
under very controlled circumstances. The original drug
approval dossier included data on a total of 78 CAPS
patients, including 9 FCAS, 63 MWS, 5 MWS/NOMID
and 1 NOMID patient with an overall exposure of 69
patient-years and a treatment duration of up to 3½ years;
therefore, the post-approval period was considered a
critical phase to gather more knowledge regarding the
short- and long-term safety, effectiveness and treatment
patterns associated with the use of the product.
To shed further light on the natural history of the dis-
ease and to observe the beneficial and adverse effects of
the treatment under real-life circumstances, an inter-
national registry was implemented.
Methods
Methods for this registry were developed in accordance
with the STROBE guidelines [7] and the Registries User’s
Guide [8]. The Registry is entirely observational. As such,no exclusion criteria were applied: all patients treated with
canakinumab are eligible to be enrolled, irrespective of
canakinumab label or other recommendations.
Likewise, as an observational study, no protocol–man-
dated visits or procedures were specified. Treatment and
diagnostic decisions regarding the patient’s disease and
care were to be determined by the physician according
to standard of care and local clinical practice. Data col-
lection was aligned with standard medical practice and
captured during routine clinic visits instead of a lock-
step periodic visit/form (no periodic follow-up or form
was required). The Registry data therefore result from
routine medical assessments performed during the initi-
ation and follow-up of canakinumab treatment, and also
depended on safety and other clinical outcomes. Data
collected at baseline, i.e. at initiation of canakinumab
therapy, included information which had otherwise already
been collected: patient characteristics (including genotype
and phenotype) and disease course, non-auto-inflammatory
related medical history, laboratory examinations, and treat-
ment with canakinumab and other medications. Treat-
ment outcomes, including indicators of effectiveness
and safety, and dosing of canakinumab treatment are
being collected over the successive five years. In routine
clinical care, most patients receive canakinumab ap-
proximately every 8 weeks at their physician’s office
(recommended data collection schedule shown in
Table 1); however it is recognized that in the clinical
setting, dosing may be delayed or interrupted due to
personal reasons, physical condition or co-morbidities.
A Steering Committee, consisting of auto-inflammatory
disease/CAPS specialists, an epidemiologist, an infectious
disease specialist and a rheumatologist, was established to
provide scientific guidance on the set-up, conduct, enrol-
ment and analysis of the Registry. The Steering Commit-
tee, recognizing the unique challenges of a Registry for
such rare conditions, also undertook the role of key in-
formant and communicator.
An enrolment target of 200 patients was established
(since the manuscript was submitted a protocol amend-
ment revised the targeted sample to 260 patients); this
choice aimed to double the numbers of patients and their
experience, previously described in the published literature.
To achieve this number, sites that had participated in
clinical trials during the development program and had
experience in the disease were asked to participate and
recommend further sites where treatment of numbers
of CAPS patients adequate to justify training and re-
cruitment was likely. Additional sites were identified in
countries (e.g. Switzerland and Belgium) in which the
participation of CAPS patients in the registry was a re-
quest of the local health authorities.
Ethical committee approval and if required, approval of
local health authorities were obtained for all participating
Table 1 CAPS registry - recommended data collection
schedule
Period Baseline
Follow-up (until study
end or premature
discontinuation)*
Timing Enrollment Every 6 months
Informed consent x
CAPS phenotype x
CAPS genotype (NLRP-3
mutation), if available
x
Non-CAPS medical history x
Vital signs (height, weight,
blood pressure)
x x
Ilaris dosing/status x x
Historical and concomitant
medications for auto-
inflammatory disease*
x x
Selected AEs* x
Other serious AEs and non-
serious adverse reactions*
x
CAPS clinical assessment * x x
CAPS-related clinical testing
results, if performed
x x
Selected local laboratory testing x x
Sexual development status
(paediatric only)
x x
Neurocognitive status
(paediatric only)
x x
Cerebrospinal fluid analysis x x
Vaccination record and outcome x x
Pregnancy status (females of
child-bearing potential only)
x
Registry disposition x
* These assessments may also be conducted during follow-up for patients who
discontinue canakinumab but remain in the Registry.
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enrolled in this registry irrespective of indication except in
those countries, e.g. Spain, where only CAPS patients
could be enrolled in accordance to local regulations. In-
formed consent and assent as appropriate under the na-
tional laws and practices in each country were signed by
the participants or in case of minors by parents and child
of adequate age.
To provide ease of data collection, expedite enrolment
and facilitate follow-up, each center was provided train-
ing in a secure, password-protected, electronic data
capture (EDC) system accessible through the internet
(www.bconfidentregistry.com), as shown in Figure 1. Ac-
cess to the EDC database has been given to all partici-
pating site personnel after they were trained on the
system. Enrolment started in November 2009 and is on-
going for children. The follow-up of enrolled patients is
ongoing and will continue for 1 year after enrolment ofthe last patient. This paper presents data entered in the
Registry by Dec 31, 2012.
Results
This recruitment strategy was successful at meeting the
enrolment targets. By December 31, 2012, 241 patients
from 43 centres in 13 countries were entered in the
registry. Out of 43 participating sites, 23 sites were uni-
versity hospitals, 5 were public hospitals, 5 private prac-
tices, and 1 was a private hospital (the information was
not available from 9 sites). Enrolling countries are shown
in Figure 2. Initial recruitment was higher in those cen-
ters that had participated in previous clinical trials: there
were 17 such sites out of the 43 (39.5%), contributing
overall with 76% of patients.
The distribution of patients at enrolment by condition,
age and gender is shown in Table 2. Of all patients
enrolled until December 2012, 80 (33%) were children
(<18 years) at the time of enrolment (of whom 4
were <4 years of age); and 47.3% were males. The majority
of patients was diagnosed with MWS (144, 59.8%), while 35
(15%) had a diagnosis of FCAS, 23 (9.5%) of NOMID
and 31 had other diagnoses (including atypical CAPS,
systemic juvenile idiopathic arthritis (SJIA), familial
Mediterranean fever (FMF) and other autoinflammatory
diseases). Information about the diagnosis is missing for
8 patients. For FCAS, the ratio of male:female was 2:1
while for the other conditions it was close to 1:1. To
monitor the safety of treatment after approval, all pa-
tients treated with canakinumab could be enrolled in
the CAPS registry independent of diagnosis. To date, 21
patients have permanently discontinued the study (i.e.
they are no longer on canakinumab), including 3 who
withdrew, 5 who were lost to follow-up, 2 who changed
physician, 1 who died and 10 for other reasons.
In the first year of recruitment only four countries were
enrolling patients, and a very low recruitment of paediat-
ric patients had been achieved (n = 10). The Steering
Committee reviewed the registry strategy and recommen-
dations were made to enhance recruitment. Identification
of national professional CAPS opinion leaders and indi-
vidual centers with relatively active CAPS programs was
adopted as a potentially successful strategy for reaching
target numbers. The automated system was well accepted
and centers reported that enrolment and follow-up be-
came progressively easier with time and practice. Thus,
the Steering Committee recommended two modifications
of the protocol. The first was an extension of enrolment
in designated sites for a second year. This was deemed
feasible and cost-effective, since once trained on the auto-
mated system, practitioners reported that they found en-
rolment of subsequent patients in their practices much
less burdensome. The analysis plan was modified to ac-
commodate such continuing enrolment and the resulting
Figure 2 Patient recruitment percentage per country. The proportion of patients recruited from each enrolling country.
Figure 1 CAPS login web page.
Tilson et al. Orphanet Journal of Rare Diseases 2013, 8:139 Page 4 of 8
http://www.ojrd.com/content/8/1/139
Table 2 Demographics and baseline characteristics of patients* enrolled (at Dec 31st, 2012)
Variable n (%) FCAS N = 35 MWS N = 144 NOMID N = 23 Others** N = 31
Gender
Male 12 (34.3) 74 (51.4) 11 (47.8) 15 (48.4)
Female 23 (65.7) 70 (48.6) 12 (52.2) 16 (51.6)
Age
< 4 years 0 2 (1.4) 0 2 (6.5)
4 - <18 years 7 (20) 35 (24.3) 14 (60.9) 17 (54.8)
≥ 18 years 28 (80) 107 (74.3) 9 (39.1) 12 (38.7)
* Information about indication is missing for 8 patients.
** Others include atypical CAPS, SJIA, FMF and other autoinflammatory diseases.
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Registry. The second modification proposed was based on
the first year’s experience of very low recruitment of
paediatric patients. Thus, it was decided to direct further
efforts towards recruitment at the new Registry sites with
a focus on paediatric patients. Figure 3 shows the annual
enrolment of paediatric patients, per country. At the end
of the second year, recruitment targets for adults were well
met and the targeted sample size was achieved. The focus
on further enrolment will be therefore limited to paediat-
ric patients.
Discussion and conclusion
As with all very rare diseases, the clinical development
program with canakinumab included a very limited num-
ber of patients for a necessarily brief period of follow-up;
therefore, the post-approval period was deemed a criticalFigure 3 Pediatric patients enrolled annually 2010-2012. The number
enrolling country.phase in which to gather more knowledge regarding the
short- and long-term safety, effectiveness and treatment
patterns associated with use of the product by clinicians
and patients. Non-intrusive, wholly observational registry
approaches are appropriate for such situations. The com-
plexity of patients’ co-medications and co-morbidities can
well be captured by an observational/registry study [9].
However, the rarity of the condition poses some specific
challenges because any one practice, even specialty prac-
tices, will likely only have a few patients, so that the
treating physician needs to have clear guidance about
which patients to include in the registry, and periodic re-
minders to keep the participation and data capture to ac-
ceptable levels. Methods for this registry were developed
in accordance with the STROBE guidelines [7] and the
Registries User’s Guide, which importantly sets up criteria
and recommendations supporting the planning, designof patients enrolled each year between 2010 and 2012 from each
Tilson et al. Orphanet Journal of Rare Diseases 2013, 8:139 Page 6 of 8
http://www.ojrd.com/content/8/1/139and implementation of registries including considerations
on data collection and quality assurance [8].
For the CAPS registry, a robust system for data collec-
tion was adopted. The CAPS registry approach features
global reach, often with national coordinators/advocates;
intensive collaboration with/ownership by opinion leaders/
referral centres; targeted local and area programs of disease
and registry awareness; and innovative low effort methods
(web-based) of data collection.
An additional challenge regarding recruitment of these
patients was due to the fact that these conditions can
not only be diagnosed by paediatricians/ paediatric rheu-
matologists, but also by specialists caring for adult
patients within and outside of rheumatology (e.g. derma-
tologists, immunologists and others). Thus, the referral
centers were encouraged to extend the net of participat-
ing centers as widely as possible. This allowed capturing
a more detailed natural history of the disease and under-
standing the gap between onset of disease and diagnosis,
and treatment.
Electronic data collection was field tested for ease of
introduction and use. It was recognized that adopting a
simple, user-friendly, and robust electronic data capture
system can facilitate the data collection process. As the
experience with the electronic data collection method
progressed, the treating physicians and their staffs
reported that they found enrolment of subsequent pa-
tients in their practices much less burdensome. One of
the challenges of a data collection system is striking a
balance between the necessary data to collect and add-
itional information that may be deemed useful for a
more in depth knowledge of the natural history of the
disease but may be perceived as burdensome by the
physician and lead to increase in missing data. Through
periodic analyses of the data, to coincide with the peri-
odic safety update reports, the team has gathered infor-
mation regarding completeness of data and initiated the
necessary measures to reduce missing data and improve
data quality, including monitoring visits to the sites,
and implementing continuous training of the participat-
ing physicians.
The continuous engagement of participating physi-
cians and centers also ensures that the follow-up of
these patients is as complete as possible and that safety
information and data related to the progression of the
disease can be reported in the registry. Continuous en-
gagement of the team ensures the patients’ follow-up is
monitored and the relatively small proportion of patients
who discontinued the study to date is testimony to the
appropriate monitoring measures in place.
Product registries, by definition, focus on patients
treated with a particular medicinal product; this kind of
registry is therefore not inclusive of all patients within a
disease category, since it does not cover those patientswho have been diagnosed with the condition but follow
a different treatment regimen. This is one of the limita-
tions of the study that prevents direct comparison of pa-
tients treated with canakinumab to those treated with
other medications. The Registry can also not be consid-
ered a complete source of data regarding the “natural
history of disease”, since, by definition, it follows only
patients who have received one or more interventions
aimed at treating their condition, and only patients with
disease progression and treatment experience warranting
initiation of a new therapy enter follow-up. However,
even such patients may provide rich history of untreated
disease at the time of enrolment. Further, the voluntary
nature of enrolment introduces other possible selection
biases. Despite these limitations product registries can
be important resources, if the representativeness and rele-
vant characteristics of the exposed population are carefully
considered, especially in the immediate post-approval set-
ting, and specifically for safety information. In this respect,
orphan drug registries may also become relevant in adap-
tive licensing approaches in which traditional drug licens-
ing (which is based on binary decisions), is transformed
into a stepwise learning process under conditions of
acknowledged uncertainty, with iterative phases of data
gathering and regulatory evaluation [10].
The convergence of short exposures to chronic treat-
ment requires creative approaches to observational
methodology, harnessing registry strategies with novel
approaches to recruitment of reporting Health Care Pro-
viders (HCPs) and monitoring of their patients.
From a strategic point of view, a registry, as part of a
post-approval program of safety monitoring, has the fol-
lowing advantages compared to a randomized clinical trial
(RCT). A registry allows collection of information about
practice in routine clinical care. All patients receiving the
treatment of interest can be included (without artificial ex-
clusions); there is no dictated treatment regimen. More-
over, a registry is conducted in “real world patients” (who
typically have higher baseline risk than patients enrolled
in RCTs) and therefore has good external validity and fi-
nally, a registry allows for prospective data collection and
for a longer term follow-up than a clinical trial.
A cheaper alternative to a registry could be repre-
sented by data collection from some form of pre-existing
database, e.g. electronic medical records or administra-
tive data (or even medical records abstraction). Such
methods have been used in other efforts to monitor rare
diseases. However the standard of care may differ be-
tween different countries, and there is no guarantee that
the data collection routinely in place for such a disease
would be comparable between different countries, or
even between different physicians in the same country.
From a methodological point of view, rare diseases
pose significant challenges for epidemiologic follow-up
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as features of this Registry can help to overcome resist-
ance to participation and facilitate comprehensive data
collection. The recruitment of experienced clinicians in
each country to assist in engaging their colleagues in
participation in the registry provides access to the net-
work of colleagues with shared interest in rare disorders.
The Advisory Board also serves as the Publications Com-
mittee for the Registry, to ensure that information about
the Registry and its emerging findings can be suitably ana-
lyzed and independently submitted for publication. The
Committee also invites the Registry investigators to submit
suggestions for publication and participate in such activ-
ities, reserving, however, all rights of access to the overall
data base to prior review and approval by the Publications
Committee in accordance with the European Network of
Centres for Pharmacoepidemiology and Pharmacovigilance
(ENCePP) code of conduct for pharmacoepidemiological
and pharmacovigilance studies [11].
An international registry can fill the knowledge gap
both by shedding light on the natural history of the dis-
ease and by monitoring the response to a new treatment
including detection and quantification of potential ad-
verse experiences and monitoring of effectiveness out-
comes. However, for rare diseases, special efforts are
needed, including identification of local opinion leaders
and electronic data capture.
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